Matinas BioPharma (MTNB) AI Stock Analysis

• Market Cap: $3.83M
• Dividend Yield: N/A
• Average Volume (3M): 52.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: N/A
• EPS Growth: 25.19%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 6,406,191
• 10 Day Avg. Volume: 45,057
• 30 Day Avg. Volume: 52,280
• PEG Ratio: 0.02
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.09
• Enterprise Value/Ebitda: -0.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.58 ▼(-10.46% Downside)

The score is primarily constrained by weak financial performance (no revenue, recurring losses, and continued cash burn) despite modest leverage. Technical indicators are mixed with only short-term stabilization and a broader downtrend, while valuation is difficult to support given negative earnings and no dividend.

Positive Factors

Lipid-based delivery platform

Matinas’s lipid-based drug-delivery technology addresses a structural industry need to improve pharmacokinetics and delivery of anti-infectives and other therapies. As a platform play, it creates durable product optionality and partnership potential across multiple indications, reducing dependence on any single candidate.

Manageable leverage

Reported modest debt relative to equity and a downward debt trend reduce near-term solvency pressure and lower interest burden risk. This structural position gives the company more flexibility for clinical funding rounds and stringently limits immediate creditor risk versus highly leveraged peers.

Reduced cash burn trend

A material narrowing in operating cash outflows signals better cost control or program prioritization, which, if sustained, lengthens the financing runway and lowers dilution risk. Structural improvement in burn is a durable positive for staying power during multi-year clinical development.

Negative Factors

No commercial revenue

Absence of operating revenue leaves the company dependent on external capital to fund R&D and operations. Over the medium term this creates persistent dilution and limits margin sustainability until commercial products or licensing revenues materialize, reducing long-term earnings visibility.

Significant cash burn

Consistently negative operating cash flow at multi‑million dollar annual rates requires repeated financings to sustain clinical programs. Even with improvement, this structural burn rate elevates financing risk and constrains strategic optionality if capital markets tighten or partnering timelines slip.

Senior finance turnover

Loss of the CFO during a capital‑intensive clinical stage increases execution and fundraising risk. For a tiny organization (few employees) this turnover can materially disrupt budgeting, investor relations and financings, creating durable operational and governance uncertainty during critical development milestones.

Matinas BioPharma Business Overview & Revenue Model

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

How the Company Makes Money

Matinas BioPharma generates revenue through the development and commercialization of its proprietary lipid nano-crystal (LNC) delivery technology. The company engages in research collaborations and license agreements to advance its drug delivery platform, which can enhance the therapeutic effectiveness of existing pharmaceuticals. Revenue is primarily derived from licensing fees, milestone payments, and potential royalties from partnerships with other biotech and pharmaceutical companies. Additionally, Matinas may receive funding from grants or government programs aimed at advancing medical research and innovation. The company's earnings are influenced by the success of its clinical trials, the establishment of strategic partnerships, and the progression of its product pipeline towards commercialization.

Matinas BioPharma Financial Statement Overview

Summary

Income statement and cash flow are very weak with zero revenue, persistent losses, and ongoing cash burn, indicating continued reliance on external funding. The balance sheet is comparatively better with modest leverage, but equity/assets have contracted and profitability remains deeply negative.

Income Statement

Operating performance remains weak with no meaningful revenue in the most recent periods (TTM (Trailing-Twelve-Months) revenue at 0; annual 2024 revenue at 0). Losses are persistent: net income was -$17.5M in TTM (Trailing-Twelve-Months) and -$24.3M in 2024, with negative operating profitability as well. While losses have narrowed versus 2024 in TTM (Trailing-Twelve-Months), the lack of a stable revenue base and continued negative margins keep overall earnings quality and visibility low.

Balance Sheet

Leverage is moderate and manageable, with total debt of $2.3M against $6.5M of equity in TTM (Trailing-Twelve-Months) (debt-to-equity ~0.36), and debt has trended down from prior years. However, the balance sheet has weakened materially over time as equity and total assets have contracted versus 2022–2023 levels, and returns on equity are deeply negative due to ongoing losses, which increases dilution and financing risk over time.

Cash Flow

Cash burn remains significant: operating cash flow was -$9.0M in TTM (Trailing-Twelve-Months) and -$15.9M in 2024, with free cash flow similarly negative. Cash burn improved in TTM (Trailing-Twelve-Months) versus 2024, but free cash flow growth is still negative in TTM (Trailing-Twelve-Months), and cash generation is not yet supported by operating revenue, implying continued dependence on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	1.10M	3.19M	33.00K	158.33K
Gross Profit	-2.46M	0.00	1.10M	-13.49M	-14.55M	-14.20M
EBITDA	-9.74M	-19.19M	-22.82M	-24.23M	-24.45M	-23.92M
Net Income	-17.48M	-24.25M	-22.94M	-21.00M	-23.28M	-22.45M
Balance Sheet
Total Assets	9.70M	12.64M	25.10M	78.87M	61.33M	70.97M
Cash, Cash Equivalents and Short-Term Investments	5.43M	7.28M	13.76M	28.81M	49.62M	58.68M
Total Debt	2.33M	2.89M	3.56M	4.12M	4.70M	3.75M
Total Liabilities	3.23M	5.05M	5.86M	42.23M	8.83M	7.24M
Stockholders Equity	6.46M	7.59M	19.25M	36.64M	52.49M	63.73M
Cash Flow
Free Cash Flow	-9.01M	-15.88M	-15.50M	-20.05M	-15.48M	-17.37M
Operating Cash Flow	-9.01M	-15.88M	-15.28M	-19.16M	-15.22M	-17.37M
Investing Cash Flow	820.00K	9.21M	13.24M	4.88M	16.77M	-40.67M
Financing Cash Flow	3.33M	9.17M	-7.00K	79.00K	6.96M	48.05M

Matinas BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.71, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.32 is Neutral, neither overbought nor oversold. The STOCH value of 25.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.

Matinas BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NCNA	46 Neutral	$10.45M	-0.02	-179.40%	―	―	94.52%
MTNB	45 Neutral	$3.83M	-0.18	-157.24%	―	―	25.19%
APRE	43 Neutral	$5.57M	-0.35	-74.72%	―	-62.75%	23.87%
HCWB	43 Neutral	$3.64M	-0.08	―	―	-87.93%	65.26%
ADIL	41 Neutral	$5.92M	-0.23	-155.01%	―	―	78.52%

Matinas BioPharma Corporate Events

Matinas BioPharma CEO Named Interim Chief Financial Officer

On November 18, 2025, Matinas BioPharma Holdings, Inc. reported that its Chief Financial Officer, Keith Kucinski, would resign effective January 17, 2026, to pursue other opportunities, and on January 22, 2026, the board appointed Chairman, President and Chief Executive Officer Jerome D. Jabbour as interim Chief Financial Officer. Jabbour, a co-founder with extensive leadership and legal experience in healthcare and pharma, will simultaneously serve as the company’s principal financial and accounting officer without changes to his existing employment terms, and the company disclosed that his appointment involved no special arrangements, family relationships, or material related-party interests.

The most recent analyst rating on (MTNB) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Matinas BioPharma stock, see the MTNB Stock Forecast page.

Matinas BioPharma Amends CEO Employment Agreement

On December 12, 2025, Matinas BioPharma Holdings, Inc. amended its employment agreement with CEO Jerome D. Jabbour, extending the deadline for a Change in Control to June 30, 2026, and modifying the payment structure for his retention bonus. The amendment also includes changes to the definitions of ‘Change in Control,’ ‘Cause,’ and ‘Good Reason,’ impacting the terms under which Mr. Jabbour can receive his bonus, reflecting strategic adjustments in the company’s executive compensation plan.

Matinas BioPharma CFO Resignation Announced

On November 18, 2025, Matinas BioPharma Holdings, Inc. announced that its Chief Financial Officer, Keith Kucinski, has decided to resign, effective January 17, 2026, to pursue other opportunities. The company clarified that his resignation was not due to any disagreements with the company’s operations, policies, or practices.